ArticleBritish journal of cancer2026

Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer.

Juanita S Lopez et al.PubMed ↗Publisher ↗

No numbers read from the abstract.